ArticleFrontiers in endocrinology2026
Type 2 diabetes is associated with pulmonary cavitation in men with HIV-TB coinfection.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To explore the association between type 2 diabetes mellitus (T2D) and pulmonary cavitation in male with HIV-tuberculosis (TB) coinfection, as well as to quantify the relationships between glycemic indicators [HbA1c and fasting plasma glucose (FPG)] and cavity size. The robustness of these correlations was further validated in a non-HIV TB sample. Methods: This comparative cross-sectional study based on exposure status included 132 men with HIV-TB and T2D (exposed group) and 131 age-matched men with HIV-TB without T2D (non-exposed group). Multivariable regression models, subgroup analyses, and interaction tests were used to evaluaterelationships and effect modification. A validation cohort of 100 non-HIV TB patients was analyzed using the same analytical framework. Results: In men coinfected with HIV and TB, T2D was linked to a higher incidence of pulmonary cavitation (adjusted OR = 3.892, 95% CI = 1.895-7.992, P<0.001). HbA1c (B = 1.039, P = 0.049) and FPG (B = 0.869, P<0.001) are positively correlated with cavity size. A notable interaction was detected between T2D and sputum positivity (P<0.001), indicating the greatest incidence of cavitation in sputum-positive T2D patients (OR = 10.492, 95% CI = 3.266-33.711). Consistent results were found in the non-HIV TB group (T2D-related cavitation OR = 4.110, P = 0.014), demonstrating that the effect of T2D is not modified by HIV status. Conclusion: T2D is a significant risk factor for pulmonary cavitation in males with HIV-TB coinfection, and poor glycemic management is linked with increased cavity size. Sputum-positive patients with T2D represent an exceptionally high-risk subgroup. Incorporating glycemic evaluation and optimal metabolic management into TB care may assist to lower cavitation risk in this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.